Press release

AB-Biotics and Scienta Farma partner to sell a pharmacogenetic test in Mexico
The Spanish biotech company AB-Biotics, listed on the Spanish Alternative Stock Market (MAB), and Scienta Farma reached an agreement to sell the pharmacogenetic test Neurofarmagen in Mexico.
This test, developed by AB-Biotics, identifies most optimum medication for each individual patient with depression, schizophrenia, bipolar disorder or epilepsy by analyzing their DNA, extracted from a sample of saliva.

Scienta Farma will have exclusive rights to distribute Neurofarmagen in Mexico. The test, presented at the 23 th National Congress of the Mexican Psychiatric Association held in September, will be released soon in this market. Mexico is the third country where Neurofarmagen will be launched. The test is already sold in Spain, marketed by Almirall, and Brazil, through GlaxoSmithKline. Over 33 million people suffer from mental disorder in Mexico according to National Comorbidity Survey, and 60% (13.3 million patients) are being treated.

About AB-Biotics

AB-Biotics is a biotechnology company focused on research, development, protection and distribution of biotech unique solutions to improve the health and wellbeing of people. Its areas of activity include the development of pharmacogenetic tests for neuropsychiatry, and probiotics and other functional ingredients for the food and pharmaceutical industries. AB-Biotics is listed on the Spanish Alternative Investment Market (MAB). The company began in 2012 its international expansion and has closed several agreements for marketing their products in America, Europe and Asia.
About Scienta Farma
Scienta Farma is a Mexican company present in both health institutional and private health sectors, formed by professionals with extensive experience in senior executive positions in international healthcare companies. With a portfolio that includes 33 different products and dosage forms for the year 2015, the company anticipates rapid growth in the coming years.
Developed by Web4Bio